Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines

다국어 초록 (Multilingual Abstract)

Nanoparticles (NPs) have distinct pharmacokinetic(PK) properties and can potentially improvethe absorption, distribution, metabolism, and elimination(ADME) of small-molecule drugs loaded therein. Owingto the unwanted toxicities of anticancer agents in healthyorgans and tissues, their precise delivery to the tumor is anessential requirement. There have been numerous advancementsin the development of nanomedicines for cancertherapy. Physiologically based PK (PBPK) models serveas excellent tools for describing and predicting the ADMEproperties and the effi cacy and toxicity of drugs, in combinationwith pharmacodynamic (PD) models. The recent preliminaryapplication of these modeling approaches to NPsdemonstrated their potential benefi ts in research and developmentprocesses relevant to the ADME and pharmacodynamicsof NPs and nanomedicines. Here, we comprehensivelyreview the pharmacokinetics of NPs, the developed PBPK models for anticancer NPs, and the developed PDmodel for anticancer agents.

참고문헌 (Reference)

1 Ivan Nestorov, "Whole-body physiologically based pharmacokinetic models" Informa Healthcare 3 (3): 235-249, 2007

2 Ivan Nestorov, "Whole Body Pharmacokinetic Models" Springer Science and Business Media LLC 42 (42): 883-908, 2003

3 Anusha Ande, "Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer" Frontiers Media SA 9 : 403-, 2018

4 Hiroshi Maeda, "Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects" American Chemical Society (ACS) 21 (21): 797-802, 2010

5 H Maeda, "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review" Elsevier BV 65 (65): 271-284, 2000

6 Song Yi Lee, "Tumor Targeting and Lipid Rafts Disrupting Hyaluronic Acid-Cyclodextrin-Based Nanoassembled Structure for Cancer Therapy" American Chemical Society (ACS) 10 (10): 36628-36640, 2018

7 Fabienne Danhier, "To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery" Elsevier BV 148 (148): 135-146, 2010

8 Peng Zhang, "Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma" Proceedings of the National Academy of Sciences 116 (116): 23714-23723, 2019

9 Kathleen M. C. Tjørve, "The use of Gompertz models in growth analyses, and new Gompertz-model approach: An addition to the Unified-Richards family" Public Library of Science (PLoS) 12 (12): e0178691-, 2017

10 E Wisse, "The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer" Springer Science and Business Media LLC 15 (15): 1193-1199, 2008

11 Minjung Cho, "The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles" Elsevier BV 189 (189): 177-183, 2009

12 Elisa Ollikainen, "The impact of porous silicon nanoparticles on human cytochrome P450 metabolism in human liver microsomes in vitro" Elsevier BV 104 : 124-132, 2017

13 Nazanin Hoshyar, "The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction" Future Medicine Ltd 11 (11): 673-692, 2016

14 Jun Fang, "The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect" Elsevier BV 63 (63): 136-151, 2011

15 You Han Bae, "Targeted drug delivery to tumors: Myths, reality and possibility" Elsevier BV 153 (153): 198-205, 2011

16 Reina E. Mebius, "Structure and function of the spleen" Springer Science and Business Media LLC 5 (5): 606-616, 2005

17 Robby A. Petros, "Strategies in the design of nanoparticles for therapeutic applications" Springer Science and Business Media LLC 9 (9): 615-627, 2010

18 Patrícia Pereira, "Smart micelleplexes as a new therapeutic approach for RNA delivery" Informa UK Limited 14 (14): 353-371, 2016

19 Lewis B. Sheiner, "Simultaneous modeling of pharmacokinetics and pharmacodynamics:application to d-tubocurarine" Wiley 25 (25): 358-371, 1979

20 Byron Ballou, "Sentinel Lymph Node Imaging Using Quantum Dots in Mouse Tumor Models" American Chemical Society (ACS) 18 (18): 389-396, 2007

21 Lorea Bueno, "Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice" Elsevier BV 44 (44): 142-150, 2008

22 Ahmed E, "Rihan FA(2012)On fractional order cancer model" 3 : 1-6, 2012

23 Diederik J.F. Nieuwenhuijs, "Response Surface Modeling of Remifentanil–Propofol Interaction on Cardiorespiratory Control and Bispectral Index" Ovid Technologies (Wolters Kluwer Health) 98 (98): 312-322, 2003

24 Hak Soo Choi, "Renal clearance of quantum dots" Springer Science and Business Media LLC 25 (25): 1165-1170, 2007

25 Jinbin Liu, "Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology" Elsevier BV 16 (16): 477-486, 2013

26 Gerhard Levy, "Relationship Between Elimination Rate of Drugs and Rate of Decline of Their Pharmacologic Effects" Elsevier BV 53 (53): 342-343, 1964

27 Wei Sang, "Recent advances in nanomaterial-based synergistic combination cancer immunotherapy" Royal Society of Chemistry (RSC) 48 (48): 3771-3810, 2019

28 Ki-Taek Kim, "Recent Progress in the Development of Poly(lactic-co-glycolic acid)-Based Nanostructures for Cancer Imaging and Therapy" MDPI AG 11 (11): E280-, 2019

29 Xijun Piao, "RNA Nanotechnology to Solubilize Hydrophobic Antitumor Drug for Targeted Delivery" Wiley 6 (6): 1900951-, 2019

30 Cheng Chang, "Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans" Springer Science and Business Media LLC 13 (13): 565-575, 2011

31 Yi-Wei Lee, "Protein Delivery into the Cell Cytosol using Non-Viral Nanocarriers" Ivyspring International Publisher 9 (9): 3280-3292, 2019

32 Terry Kenakin, "Principles: Receptor theory in pharmacology" Elsevier BV 25 (25): 186-192, 2004

33 P. LEES, "Principles of pharmacodynamics and their applications in veterinary pharmacology" Wiley 27 (27): 397-414, 2004

34 Monica Simeoni, "Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents" American Association for Cancer Research (AACR) 64 (64): 1094-1101, 2004

35 John P. Gibbs, "Prediction of Exposure–Response Relationships to Support First-in-Human Study Design" Springer Science and Business Media LLC 12 (12): 750-758, 2010

36 M. Rocchetti, "Predicting the active doses in humans from animal studies: A novel approach in oncology" Elsevier BV 43 (43): 1862-1868, 2007

37 Brian Higgins, "Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach" American Association for Cancer Research (AACR) 20 (20): 3742-3752, 2014

38 Armin W. Opitz, "Physiologically Based Pharmacokinetics of Molecular Imaging Nanoparticles for mRNA Detection Determined in Tumor-Bearing Mice" Mary Ann Liebert Inc 20 (20): 117-125, 2010

39 Dongfen Yuan, "Physiologically Based Pharmacokinetic Modeling of Nanoparticles" Elsevier BV 108 (108): 58-72, 2019

40 Mingguang Li, "Physiologically Based Pharmacokinetic Modeling of Nanoparticles" American Chemical Society (ACS) 4 (4): 6303-6317, 2010

41 MJ Gilkey, "Physiologically Based Pharmacokinetic Modeling of Fluorescently Labeled Block Copolymer Nanoparticles for Controlled Drug Delivery in Leukemia Therapy" Wiley 4 (4): 167-174, 2015

42 Donald E. Mager, "Physiologically Based Pharmacokinetic Model for Composite Nanodevices: Effect of Charge and Size on In Vivo Disposition" Springer Science and Business Media LLC 29 (29): 2534-2542, 2012

43 Min Li, "Physiologically Based Pharmacokinetic (PBPK) Modeling of Pharmaceutical Nanoparticles" Springer Science and Business Media LLC 19 (19): 26-42, 2017

44 Jennifer E. Sager, "Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification" American Society for Pharmacology & Experimental Therapeutics (ASPET) 43 (43): 1823-1837, 2015

45 Selvan Ravindran, "Pharmacokinetics, Metabolism, Distribution and Permeability of Nanomedicine" Bentham Science Publishers Ltd. 19 (19): 327-334, 2018

46 Alberto Gabizon, "Pharmacokinetics of Pegylated Liposomal Doxorubicin" Springer Science and Business Media LLC 42 (42): 419-436, 2003

47 Nianhang Chen, "Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel" Wiley 54 (54): 1097-1107, 2014

48 Dandan Luo, "Pharmacokinetics and pharmacodynamics of liposomal chemophototherapy with short drug-light intervals" Elsevier BV 297 : 39-47, 2019

49 H. Harashima, "Pharmacokinetic/pharmacodynamic modeling of antitumor agents encapsulated into liposomes" Elsevier BV 40 (40): 39-61, 1999

50 Laurent Salphati, "Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Inhibition and Biomarker Modulation by the Novel Phosphatidylinositol 3-Kinase Inhibitor GDC-0941" American Society for Pharmacology & Experimental Therapeutics (ASPET) 38 (38): 1436-1442, 2010

51 Shinji Yamazaki, "Pharmacokinetic-Pharmacodynamic Modeling of Biomarker Response and Tumor Growth Inhibition to an Orally Available cMet Kinase Inhibitor in Human Tumor Xenograft Mouse Models" American Society for Pharmacology & Experimental Therapeutics (ASPET) 36 (36): 1267-1274, 2008

52 Akifumi Kogame, "Pharmacokinetic and Pharmacodynamic Modeling of Hedgehog Inhibitor TAK-441 for the Inhibition of Gli1 messenger RNA Expression and Antitumor Efficacy in Xenografted Tumor Model Mice" American Society for Pharmacology & Experimental Therapeutics (ASPET) 41 (41): 727-734, 2013

53 Wojciech Krzyzanski, "Pharmacodynamic models of age-structured cell populations" Springer Science and Business Media LLC 42 (42): 573-589, 2015

54 Evelyn D. Lobo, "Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro" Springer Science and Business Media LLC 4 (4): 212-222, 2002

55 Zamboni WC, "Pharmacodynamic model of topotecan-induced time course of neutropenia" 7 : 2301-2308, 2001

56 Thomas W. Bouillon, "Pharmacodynamic Interaction between Propofol and Remifentanil Regarding Hypnosis, Tolerance of Laryngoscopy, Bispectral Index, and Electroencephalographic Approximate Entropy" Ovid Technologies (Wolters Kluwer Health) 100 (100): 1353-1372, 2004

57 Raymond S.H. Yang, "Persistent Tissue Kinetics and Redistribution of Nanoparticles, Quantum Dot 705, in Mice: ICP-MS Quantitative Assessment" Environmental Health Perspectives 115 (115): 1339-1343, 2007

58 A. Ruggiero, "Paradoxical glomerular filtration of carbon nanotubes" Proceedings of the National Academy of Sciences 107 (107): 12369-12374, 2010

59 Dominique Barbolosi, "Optimizing drug regimens in cancer chemotherapy: a simulation study using a PK–PD model" Elsevier BV 31 (31): 157-172, 2001

60 Hideyoshi Harashima, "Optimization of antitumor effect of liposomally encapsulated doxorubicin based on simulations by pharmacokinetic/pharmacodynamic modeling" Elsevier BV 61 (61): 93-106, 1999

61 Barrett E. Rabinow, "Nanosuspensions in drug delivery" Springer Science and Business Media LLC 3 (3): 785-796, 2004

62 Beeravelli Sudhakar, "Nanosuspensions as a Versatile Carrier based Drug Delivery System – An Overview" Bentham Science Publishers Ltd. 11 (11): 299-305, 2014

63 Yi-Nan Zhang, "Nanoparticle–liver interactions: Cellular uptake and hepatobiliary elimination" Elsevier BV 240 : 332-348, 2016

64 Anthony Seaton, "Nanoparticles, human health hazard and regulation" The Royal Society 7 (7): S119-S129, 2010

65 Amir H. Faraji, "Nanoparticles in cellular drug delivery" Elsevier BV 17 (17): 2950-2962, 2009

66 Heather Herd Gustafson, "Nanoparticle uptake: The phagocyte problem" Elsevier BV 10 (10): 487-510, 2015

67 Lisa Brannon-Peppas, "Nanoparticle and targeted systems for cancer therapy" Elsevier BV 56 (56): 1649-1659, 2004

68 최영희, "Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics" 한국약제학회 48 (48): 43-60, 2018

69 S. Moein Moghimi, "Nanomedicine: current status and future prospects" Wiley 19 (19): 311-330, 2004

70 Ramya Dhandapani, "Nanohybrids – cancer theranostics for tiny tumor clusters" Elsevier BV 299 : 21-30, 2019

71 Xiaoqin Qian, "Nanocatalysts-augmented Fenton chemical reaction for nanocatalytic tumor therapy" Elsevier BV 211 : 1-13, 2019

72 Quoc‑Viet Le, "Nano delivery systems and cancer immunotherapy" 한국약제학회 48 (48): 527-539, 2018

73 Samuel K. Lai, "Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues" Elsevier BV 61 (61): 158-171, 2009

74 Jong Hyuk Byun, "Modeling to capture bystander-killing effect by released payload in target positive tumor cells" Springer Science and Business Media LLC 19 (19): 194-, 2019

75 Nelson L. Jumbe, "Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice" Springer Science and Business Media LLC 37 (37): 221-242, 2010

76 Macheras P, "Modeling in biopharmaceutics, pharmacokinetics, and pharmacodynamics" 30 : 3-14, 2006

77 Lena E. Friberg, "Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs" American Society of Clinical Oncology (ASCO) 20 (20): 4713-4721, 2002

78 Song Yi Lee, "Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer" American Chemical Society (ACS) 20 (20): 835-845, 2019

79 홍석호, "Mesoporous silica-based nanoplatforms for the delivery of photodynamic therapy agents" 한국약제학회 48 (48): 3-17, 2018

80 Jillian L. Perry, "Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location" American Chemical Society (ACS) 17 (17): 2879-2886, 2017

81 Shinji Yamazaki, "Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase" American Society for Pharmacology & Experimental Therapeutics (ASPET) 43 (43): 54-62, 2014

82 Felmlee MA, "Mechanism-based pharmacodynamic modeling" 929 : 583-600, 2012

83 Moghimi SM, "Long-circulating and target-specifi c nanoparticles : theory to practice" 53 : 283-318, 2001

84 Johanne Poisson, "Liver sinusoidal endothelial cells: Physiology and role in liver diseases" Elsevier BV 66 (66): 212-227, 2017

85 윤성원, "Liposomal itraconazole formulation for the treatment of glioblastoma using inclusion complex with HP-β-CD" 한국약제학회 49 (49): 477-483, 2019

86 R. Nagashima, "Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin" Wiley 10 (10): 22-35, 1969

87 Seyed Mohammadali Dadfar, "Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications" Elsevier BV 138 : 302-325, 2019

88 Suvi K. Soininen, "Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling" American Chemical Society (ACS) 13 (13): 1358-1365, 2016

89 Hironobu Minami, "Indirect-response model for the time course of leukopenia with anticancer drugs*" Springer Science and Business Media LLC 64 (64): 511-521, 1998

90 Vahid Mirshafiee, "Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake" Elsevier BV 75 : 295-304, 2016

91 K Yoshida, "Impact of Physiologically Based Pharmacokinetic Models on Regulatory Reviews and Product Labels: Frequent Utilization in the Field of Oncology" Wiley 101 (101): 597-602, 2017

92 Carl-Henrik Heldin, "High interstitial fluid pressure — an obstacle in cancer therapy" Springer Science and Business Media LLC 4 (4): 806-813, 2004

93 Norton L, "Growth curve of an experimental solid tumor following radiotherapy" 58 : 1735-1741, 1977

94 Zhanjun Gu, "Graphene-Based Smart Platforms for Combined Cancer Therapy" Wiley 31 (31): e1800662-, 2019

95 Lian‐Hua Fu, "Glucose Oxidase‐Instructed Multimodal Synergistic Cancer Therapy" Wiley 31 (31): e1808325-, 2019

96 Christopher N. Angstmann, "Fractional Order Compartment Models" Society for Industrial & Applied Mathematics (SIAM) 77 (77): 430-446, 2017

97 Yanchun Wei, "Factors relating to the biodistribution & clearance of nanoparticles & their eff ects on in vivo application" Future Medicine Ltd 13 (13): 1495-1512, 2018

98 S.M. Moghimi, "Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective" Annual Reviews 52 (52): 481-503, 2012

99 MC Bissery, "Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice" Ovid Technologies (Wolters Kluwer Health) 7 (7): 437-460, 1996

100 전근우, "Enhanced photodyamic therapy via photosensitizer-loaded nanoparticles for cancer treatment" 한국약제학회 49 (49): 1-8, 2019

101 Khaled Greish, "Enhanced permeability and retention effect for selective targeting of anticancer nanomedicine: are we there yet?" Elsevier BV 9 (9): e161-e166, 2012

102 Huijing Xiang, "Energy‐Converting Nanomedicine" Wiley 15 (15): 1805339-, 2019

103 Morteza Mahmoudi, "Emerging understanding of the protein corona at the nano-bio interfaces" Elsevier BV 11 (11): 817-832, 2016

104 Baojian Wu, "Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112" Informa UK Limited 10 : 2521-2535, 2015

105 Vail DM, "Effi cacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated(stealth)liposomes : a randomized, double-blind clinical trial using a canine model" 4 : 1567-1571, 1998

106 Joseph W. Nichols, "EPR: Evidence and fallacy" Elsevier BV 190 : 451-464, 2014

107 Anna Kane Laird, "Dynamics of Tumor Growth" Springer Science and Business Media LLC 18 (18): 490-502, 1964

108 Twan Lammers, "Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress" Elsevier BV 161 (161): 175-187, 2012

109 Caterina Guiot, "Does tumor growth follow a “universal law”?" Elsevier BV 225 (225): 147-151, 2003

110 Hope Murphy, "Differences in predictions of ODE models of tumor growth: a cautionary example" Springer Science and Business Media LLC 16 (16): 163-, 2016

111 Gerald J. Fetterly, "Development of a Preclinical PK/PD Model to Assess Antitumor Response of a Sequential Aflibercept and Doxorubicin-Dosing Strategy in Acute Myeloid Leukemia" Springer Science and Business Media LLC 15 (15): 662-673, 2013

112 Spratt JA, "Decelerating growth and human breast cancer" 71 : 2013-2019, 1993

113 Angstmann CN, "Continuous time random walks with reactions forcing and trapping" 8 : 17-27, 2013

114 Natalie L. Dayneka, "Comparison of four basic models of indirect pharmacodynamic responses" Springer Science and Business Media LLC 21 (21): 457-478, 1993

115 Jun Yang, "Comparison of Two Pharmacodynamic Transduction Models for the Analysis of Tumor Therapeutic Responses in Model Systems" Springer Science and Business Media LLC 12 (12): 1-10, 2010

116 황희숙, "Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy" 한국약제학회 48 (48): 143-151, 2018

117 Mi‑Kyung Lee, "Clinical usefulness of liposomal formulations in cancer therapy: lessons from the experiences of doxorubicin" 한국약제학회 49 (49): 203-214, 2019

118 Michelle Longmire, "Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats" Future Medicine Ltd 3 (3): 703-717, 2008

119 Sébastien Benzekry, "Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth" Public Library of Science (PLoS) 10 (10): e1003800-, 2014

120 Uma Prabhakar, "Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology" American Association for Cancer Research (AACR) 73 (73): 2412-2417, 2013

121 Karim Y. Helmy, "CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens" Elsevier BV 124 (124): 915-927, 2006

122 Christina von Roemeling, "Breaking Down the Barriers to Precision Cancer Nanomedicine" Elsevier BV 35 (35): 159-171, 2017

123 Qian Chen, "Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy" American Chemical Society (ACS) 19 (19): 4879-4889, 2019

124 Torsten Hansen, "Biological tolerance of different materials in bulk and nanoparticulate form in a rat model: sarcoma development by nanoparticles" The Royal Society 3 (3): 767-775, 2006

125 Ganeshchandra Sonavane, "Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size" Elsevier BV 66 (66): 274-280, 2008

126 Shive MS, "Biodegradation and biocompatibility of PLA and PLGA microspheres" 28 : 5-24, 1997

127 Kentaro Furumoto, "Biliary excretion of polystyrene microspheres depends on the type of receptor-mediated uptake in rat liver" Elsevier BV 1526 (1526): 221-226, 2001

128 P Zhao, "Best Practice in the Use of Physiologically Based Pharmacokinetic Modeling and Simulation to Address Clinical Pharmacology Regulatory Questions" Springer Science and Business Media LLC 92 (92): 17-20, 2012

129 Dhaval K. Shah, "Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin" Springer Science and Business Media LLC 39 (39): 643-659, 2012

130 RN Upton, "Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3-Introduction to Pharmacodynamic Modeling Methods" Wiley 3 (3): e88-, 2014

131 DR Mould, "Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development-Part 2: Introduction to Pharmacokinetic Modeling Methods" Wiley 2 (2): e38-, 2013

132 HM Jones, "Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development" Wiley 2 (2): e63-, 2013

133 Yanguang Cao, "Applications of minimal physiologically-based pharmacokinetic models" Springer Science and Business Media LLC 39 (39): 711-723, 2012

134 A. G. M'Kendrick, "Applications of Mathematics to Medical Problems" Cambridge University Press (CUP) 44 : 98-130, 1925

135 Harvey Wong, "Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response" American Association for Cancer Research (AACR) 18 (18): 3846-3855, 2012

136 Sebastien Taurin, "Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?" Elsevier BV 164 (164): 265-275, 2012

137 Dethlefsen LA, "Analysis of tumor growth curves" 40 : 389-405, 1968

138 Stefan Wilhelm, "Analysis of nanoparticle delivery to tumours" Springer Science and Business Media LLC 1 (1): 2016

139 Song Yi Lee, "An α-tocopheryl succinate enzyme-based nanoassembly for cancer imaging and therapy" Informa UK Limited 25 (25): 738-749, 2018

140 LE Friberg, "An Agonist–Antagonist Interaction Model for Prolactin Release Following Risperidone and Paliperidone Treatment" Springer Science and Business Media LLC 85 (85): 409-417, 2008

141 Jacques Bélair, "Age-structured and two-delay models for erythropoiesis" Elsevier BV 128 (128): 317-346, 1995

142 Xuewen He, "AIE Featured Inorganic–Organic Core@Shell Nanoparticles for High-Efficiency siRNA Delivery and Real-Time Monitoring" American Chemical Society (ACS) 19 (19): 2272-2279, 2019

143 William J. Jusko, "A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents" Springer Science and Business Media LLC 1 (1): 175-200, 1973

144 Benjamin Ribba, "A model of vascular tumour growth in mice combining longitudinal tumour size data with histological biomarkers" Elsevier BV 47 (47): 479-490, 2011

145 P. Magni, "A mathematical model to study the effects of drugs administration on tumor growth dynamics" Elsevier BV 200 (200): 127-151, 2006

146 John Carl Panetta, "A mathematical model of breast and ovarian cancer treated with paclitaxel" Elsevier BV 146 (146): 89-113, 1997

147 Maria Ohlson, "A gel-membrane model of glomerular charge and size selectivity in series" American Physiological Society 280 (280): F396-F405, 2001

148 Sung JH, "A combined pharmacokinetic–pharmacodynamic (PK–PD) model for tumor growth in the rat with UFT administration" 98 : 1885-1904, 2009

149 Alexander B. Herman, "A Quantitative Theory of Solid Tumor Growth, Metabolic Rate and Vascularization" Public Library of Science (PLoS) 6 (6): e22973-, 2011

150 Christina Vasalou, "A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design" Public Library of Science (PLoS) 10 (10): e0118977-, 2015

151 Aman Singh, "A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs" MDPI AG 11 (11): 98-, 2019